These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 1808112)

  • 21. Detection of iron(III) chelate separated by reversed-phase high-performance liquid chromatography.
    Wang YM; Cheng TH
    Kaohsiung J Med Sci; 1996 May; 12(5):267-73. PubMed ID: 8676431
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantification of desferrioxamine and its iron chelating metabolites by high-performance liquid chromatography and simultaneous ultraviolet-visible/radioactive detection.
    Singh S; Mohammed N; Ackerman R; Porter JB; Hider RC
    Anal Biochem; 1992 May; 203(1):116-20. PubMed ID: 1524206
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantitation of MR relaxation effects of iron oxide particles in liver and spleen.
    Majumdar S; Zoghbi S; Pope CF; Gore JC
    Radiology; 1988 Dec; 169(3):653-8. PubMed ID: 3186986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Paramagnetic pharmaceuticals for magnetic resonance imaging.
    Wesbey GE; Engelstad BL; Brasch RC
    Physiol Chem Phys Med NMR; 1984; 16(2):145-55. PubMed ID: 6095341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Studies in desferrioxamine and ferrioxamine metabolism in normal and iron-loaded subjects.
    Summers MR; Jacobs A; Tudway D; Perera P; Ricketts C
    Br J Haematol; 1979 Aug; 42(4):547-55. PubMed ID: 476006
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro stability analyses as a model for metabolism of ferromagnetic particles (Clariscan), a contrast agent for magnetic resonance imaging.
    Skotland T; Sontum PC; Oulie I
    J Pharm Biomed Anal; 2002 Apr; 28(2):323-9. PubMed ID: 11929675
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evidence for attachment of magnetic starch microspheres to Kupffer cells receptors in excised and perfused rat liver.
    Colet JM; Van Haverbeke Y; Muller RN
    Invest Radiol; 1994 Jun; 29 Suppl 2():S223-5. PubMed ID: 7928238
    [No Abstract]   [Full Text] [Related]  

  • 28. Imaging circulating cells and lymphoid tissues with iron oxide nanoparticles.
    Elias A; Tsourkas A
    Hematology Am Soc Hematol Educ Program; 2009; ():720-6. PubMed ID: 20008258
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prooxidant activity of ferrioxamine in isolated rat hepatocytes and linoleic acid micelles.
    Bergamini S; Rota C; Staffieri M; Tomasi A; Iannone A
    Chem Res Toxicol; 1999 Apr; 12(4):365-70. PubMed ID: 10207126
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Science to practice: imaging of cellular microparticles--magic dust or just dirt?
    Choyke PL
    Radiology; 2012 Apr; 263(1):1-2. PubMed ID: 22438438
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Paramagnetic iron (III) MRI contrast agents.
    White DL
    Magn Reson Med; 1991 Dec; 22(2):309-12. PubMed ID: 1812362
    [No Abstract]   [Full Text] [Related]  

  • 32. A thermodynamic description of the binding of iron to ferrioxamine B in aqueous solutions.
    Gould BL; Langerman N
    Arch Biochem Biophys; 1982 Apr; 215(1):148-56. PubMed ID: 7092222
    [No Abstract]   [Full Text] [Related]  

  • 33. Superparamagnetic contrast agents for magnetic resonance imaging.
    Gundersen HG; Bach-Gansmo T; Holtz E; Fahlvik AK; Berg A
    Invest Radiol; 1990 Sep; 25 Suppl 1():S67-8. PubMed ID: 2283261
    [No Abstract]   [Full Text] [Related]  

  • 34. High-performance liquid chromatographic analysis of desferrioxamine using a metal-free system.
    Venkataram S; Rahman YE
    J Chromatogr; 1987 Dec; 411():494-7. PubMed ID: 3443636
    [No Abstract]   [Full Text] [Related]  

  • 35. Assessing effective transvascular particle delivery to the brain parenchyma: a challenge to neuroradiology.
    Quencer RM
    AJNR Am J Neuroradiol; 1999 Feb; 20(2):186. PubMed ID: 10094333
    [No Abstract]   [Full Text] [Related]  

  • 36. Recent insights into interactions of deferoxamine with cellular and plasma iron pools: Implications for clinical use.
    Porter JB; Rafique R; Srichairatanakool S; Davis BA; Shah FT; Hair T; Evans P
    Ann N Y Acad Sci; 2005; 1054():155-68. PubMed ID: 16339661
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An expedient reverse-phase high-performance chromatography (RP-HPLC) based method for high-throughput analysis of deferoxamine and ferrioxamine in urine.
    Arshad B; Iqbal T; Akram S; Mushtaq M
    Biomed Chromatogr; 2017 Feb; 31(2):. PubMed ID: 27503066
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Do we need more iron-chelating drugs?
    Kontoghiorghes GJ
    Lancet; 2003 Aug; 362(9382):495-6. PubMed ID: 12927446
    [No Abstract]   [Full Text] [Related]  

  • 39. [Pharmacological properties of complex iron oxide nanoparticles entering in magnetic resonance tomography contrast agent].
    Akopdzhanov AG; Sergeev AI; Manvelov EV; Semeĭkin AV; Naumenko VIu; Panov VO; Bykov IV; Shimanovskiĭ NL
    Eksp Klin Farmakol; 2010 Jun; 73(6):23-8. PubMed ID: 20726347
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The measurement of the amount of iron (III) complexes with desferal in the perfused rat liver by an EPR method].
    Kozlov AV; Vladimirov IuA; Azizova OA
    Biull Eksp Biol Med; 1989 May; 107(5):577-9. PubMed ID: 2544235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.